JP2008514227A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008514227A5 JP2008514227A5 JP2007534532A JP2007534532A JP2008514227A5 JP 2008514227 A5 JP2008514227 A5 JP 2008514227A5 JP 2007534532 A JP2007534532 A JP 2007534532A JP 2007534532 A JP2007534532 A JP 2007534532A JP 2008514227 A5 JP2008514227 A5 JP 2008514227A5
- Authority
- JP
- Japan
- Prior art keywords
- polynucleotide
- polypeptide
- sequence
- seq
- muscle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091033319 polynucleotide Proteins 0.000 claims description 109
- 102000040430 polynucleotide Human genes 0.000 claims description 109
- 239000002157 polynucleotide Substances 0.000 claims description 109
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 52
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 49
- 229920001184 polypeptide Polymers 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 43
- 239000002773 nucleotide Substances 0.000 claims description 29
- 125000003729 nucleotide group Chemical group 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 26
- 210000003205 muscle Anatomy 0.000 claims description 20
- 239000013598 vector Substances 0.000 claims description 20
- 230000000295 complement effect Effects 0.000 claims description 19
- 108090000790 Enzymes Proteins 0.000 claims description 17
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 230000014509 gene expression Effects 0.000 claims description 17
- 241001465754 Metazoa Species 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 230000000692 anti-sense effect Effects 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 239000000556 agonist Substances 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 239000005557 antagonist Substances 0.000 claims description 6
- 102000004961 Furin Human genes 0.000 claims description 5
- 108090001126 Furin Proteins 0.000 claims description 5
- 101710118538 Protease Proteins 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 5
- 230000037257 muscle growth Effects 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 3
- 230000002452 interceptive effect Effects 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 230000002441 reversible effect Effects 0.000 claims description 3
- 201000000585 muscular atrophy Diseases 0.000 claims 17
- 206010028289 Muscle atrophy Diseases 0.000 claims 13
- 230000020763 muscle atrophy Effects 0.000 claims 10
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 4
- 208000030507 AIDS Diseases 0.000 claims 3
- 206010006895 Cachexia Diseases 0.000 claims 3
- 206010061216 Infarction Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000007574 infarction Effects 0.000 claims 3
- 201000006938 muscular dystrophy Diseases 0.000 claims 3
- 230000002107 myocardial effect Effects 0.000 claims 3
- 210000004165 myocardium Anatomy 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 206010028311 Muscle hypertrophy Diseases 0.000 claims 2
- 108091030071 RNAI Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000001010 compromised effect Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 230000012042 muscle hypertrophy Effects 0.000 claims 2
- 230000003387 muscular Effects 0.000 claims 2
- 210000003098 myoblast Anatomy 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 230000002797 proteolythic effect Effects 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 241000282994 Cervidae Species 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 241000283086 Equidae Species 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 238000000636 Northern blotting Methods 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 241000286209 Phasianidae Species 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 241000282887 Suidae Species 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 108010091748 peptide A Proteins 0.000 claims 1
- 244000144977 poultry Species 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ535696 | 2004-09-30 | ||
| NZ53569604A NZ535696A (en) | 2004-09-30 | 2004-09-30 | Myostatin splice variants ( MSV ) |
| NZ538396 | 2005-02-22 | ||
| NZ53839605 | 2005-02-22 | ||
| PCT/NZ2005/000250 WO2006036074A1 (en) | 2004-09-30 | 2005-09-30 | Myostatin isoform |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008514227A JP2008514227A (ja) | 2008-05-08 |
| JP2008514227A5 true JP2008514227A5 (enExample) | 2008-10-23 |
| JP5335239B2 JP5335239B2 (ja) | 2013-11-06 |
Family
ID=36119161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007534532A Expired - Fee Related JP5335239B2 (ja) | 2004-09-30 | 2005-09-30 | ミオスタチンアイソフォーム |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20080118487A1 (enExample) |
| EP (1) | EP1799709B1 (enExample) |
| JP (1) | JP5335239B2 (enExample) |
| AT (1) | ATE552272T1 (enExample) |
| CA (1) | CA2582940A1 (enExample) |
| WO (1) | WO2006036074A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100898149B1 (ko) | 2007-04-05 | 2009-05-19 | 주식회사 에스엔피 제네틱스 | 소의 근내지방도와 연관되어 있는 티틴-캡 다형성 |
| EP2981822B1 (en) | 2013-05-06 | 2020-09-02 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| WO2019195679A1 (en) * | 2018-04-06 | 2019-10-10 | Intrexon Corporation | Tilapia with enhanced growth characteristics |
| US12202869B2 (en) | 2019-03-01 | 2025-01-21 | Knc Laboratories Co., Ltd. | Inhibition of myostatin signal by myostatin splice variant-derived protein and utilization thereof |
| CN115201474A (zh) * | 2022-08-12 | 2022-10-18 | 万华普曼生物工程有限公司 | 一种新型冠状病毒抗体的快速检测试剂盒及其制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4487325A (en) | 1982-07-06 | 1984-12-11 | Owens-Illinois, Inc. | Crown closures and containers |
| US7393682B1 (en) * | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| US5874409A (en) * | 1995-06-07 | 1999-02-23 | La Jolla Pharmaceutical Company | APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies |
| WO1998033887A1 (en) | 1997-02-05 | 1998-08-06 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| US6656475B1 (en) * | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| US6369201B1 (en) | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
| JP2003506325A (ja) | 1999-07-20 | 2003-02-18 | ファーメクサ エイ／エス | Ｇｄｆ−８活性のダウン−レギュレート方法 |
| AU782925B2 (en) * | 2000-01-18 | 2005-09-08 | Orico Limited | Myostatin and mimetics thereof |
| CN1650012A (zh) | 2002-07-24 | 2005-08-03 | 英特塞尔股份公司 | 来自致病病毒的备选阅读框所编码的抗原 |
| DE60331778D1 (de) * | 2002-09-16 | 2010-04-29 | Univ Johns Hopkins | Metalloproteaseaktivierung von myostatin und verfahren zur modulation der myostatinaktivität |
| NZ529860A (en) * | 2003-11-28 | 2006-10-27 | Ovita Ltd | Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases |
| WO2005066204A2 (en) * | 2003-12-31 | 2005-07-21 | Schering-Plough Ltd. | Neutralizing epitope-based growth enhancing vaccine |
| NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| US20070190056A1 (en) | 2006-02-07 | 2007-08-16 | Ravi Kambadur | Muscle regeneration compositions and uses therefor |
| JP2009545313A (ja) * | 2006-08-03 | 2009-12-24 | オリコ・リミテッド | ミオスタチンアンタゴニスト |
-
2005
- 2005-09-30 JP JP2007534532A patent/JP5335239B2/ja not_active Expired - Fee Related
- 2005-09-30 EP EP05790714A patent/EP1799709B1/en not_active Expired - Lifetime
- 2005-09-30 US US11/576,449 patent/US20080118487A1/en not_active Abandoned
- 2005-09-30 CA CA002582940A patent/CA2582940A1/en not_active Abandoned
- 2005-09-30 WO PCT/NZ2005/000250 patent/WO2006036074A1/en not_active Ceased
- 2005-09-30 AT AT05790714T patent/ATE552272T1/de active
-
2011
- 2011-04-12 US US13/085,263 patent/US8455448B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007297407A5 (enExample) | ||
| JP2005512515A5 (enExample) | ||
| JP2002522016A (ja) | 神経内分泌特異的タンパク質に類似したタンパク質、およびそれをコードするｃＤＮＡ | |
| CN109563516A (zh) | Gpr156变体及其用途 | |
| Tanioka et al. | Regulation of the human leukocyte‐derived arginine aminopeptidase endoplasmic reticulum‐aminopeptidase 2 gene by interferon‐γ | |
| JP2008514227A5 (enExample) | ||
| JP2002533115A5 (enExample) | ||
| JP2005528080A5 (enExample) | ||
| JPH09509319A (ja) | Ｒｎａ修正酵素およびその使用方法 | |
| CA2507716C (en) | Novel adaptor protein that binds to mammalian toll-like receptor 3, and gene thereof | |
| JP2003510027A (ja) | Ｐｇｐｃｒ−３ポリペプチドおよびそのｄｎａ配列 | |
| KR20040010169A (ko) | 신규 ｇ 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이의이용 | |
| JP2001521388A (ja) | グリシン輸送体 | |
| Edgar et al. | Bone morphogenetic protein‐2 induces expression of murine zinc finger transcription factor ZNF450 | |
| JPH11318452A (ja) | ヒト脳からの新規ｇ蛋白質―結合レセプタ― | |
| EP1219638A2 (en) | G-protein coupled receptors having homology to the P2Y purinoreceptor 1 (P2Y1) | |
| WO2001046414A1 (fr) | Nouvelle proteine receptrice couplee a la proteine de fixation de guanosine triphosphate, bg26 | |
| JP2006516888A5 (enExample) | ||
| JP2006525782A5 (enExample) | ||
| JP2005528886A5 (enExample) | ||
| US20040137574A1 (en) | Novel polypeptide | |
| US7183397B2 (en) | NK-2 homeobox transcription factor | |
| JP2003315332A5 (enExample) | ||
| EP1215214A1 (en) | Novel polypeptide | |
| JP2004500864A (ja) | 新規ｇ−タンパク質共役型受容体 |